Key Takeaways:
- FDA extends review for subcutaneous Sarclisa by up to three months.
- The delay affects the drug's use in treating multiple myeloma.
- Sanofi's stock may see pressure from the prolonged uncertainty.
Back
Back
Sanofi's Sarclisa decision delayed by 3 months by the FDA
The US Food and Drug Administration (FDA) has extended its review of Sanofi's subcutaneous formulation of Sarclisa by up to three months, delaying a decision on the multiple myeloma treatment.
"This is a minor setback for Sanofi, but it does introduce a level of uncertainty for investors," said fictional analyst John Doe from a fictional firm "Pharma Capital". "The market was anticipating a timely approval to compete more effectively."
The target action date for the biologics license application for Sarclisa (isatuximab-irfc) has been pushed back. The application covers the subcutaneous version for all currently approved indications of the intravenous formulation in the US.
The delay could postpone a significant revenue stream for Sanofi and allow competitors in the crowded multiple myeloma market to solidify their positions. The subcutaneous formulation is expected to offer more convenience for patients compared to the intravenous version.
The extension was announced by Sanofi on April 22, 2026. The company did not disclose specific reasons for the FDA's decision to extend the review period.
Sarclisa is a monoclonal antibody that targets the CD38 protein found on the surface of multiple myeloma cells. The intravenous version is already approved in combination with other standard-of-care regimens.
The potential approval of a subcutaneous formulation is a key part of Sanofi's strategy to make Sarclisa a more competitive and convenient option for patients. Competing treatments, such as Johnson & Johnson's Darzalex, are already available in a subcutaneous formulation.
The three-month delay puts Sanofi further behind in the race for patient convenience in the multiple myeloma space. Investors will be closely watching for the FDA's final decision, which is now expected in the third quarter of 2026.
This article is for informational purposes only and does not constitute investment advice.
